vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and New Fortress Energy Inc. (NFE). Click either name above to swap in a different company.
New Fortress Energy Inc. is the larger business by last-quarter revenue ($326.2M vs $183.1M, roughly 1.8× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -259.7%, a 273.0% gap on every dollar of revenue. On growth, Amphastar Pharmaceuticals, Inc. posted the faster year-over-year revenue change (-1.8% vs -7.0%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $-134.8M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -26.8%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
New Fortress Energy Inc. is a global energy infrastructure firm developing, owning and operating LNG import/export terminals, natural gas supply networks and low-carbon projects. It serves utility, industrial and public sector clients across the Americas and Caribbean, delivering affordable, lower-emission energy resources.
AMPH vs NFE — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $326.2M |
| Net Profit | $24.4M | $-847.1M |
| Gross Margin | 46.8% | 35.5% |
| Operating Margin | 19.4% | -193.0% |
| Net Margin | 13.3% | -259.7% |
| Revenue YoY | -1.8% | -7.0% |
| Net Profit YoY | -35.7% | -277.4% |
| EPS (diluted) | $0.51 | $-3.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $326.2M | ||
| Q3 25 | $191.8M | $240.3M | ||
| Q2 25 | $174.4M | $228.1M | ||
| Q1 25 | $170.5M | $384.9M | ||
| Q4 24 | $186.5M | $350.7M | ||
| Q3 24 | $191.2M | $446.0M | ||
| Q2 24 | $182.4M | $291.2M | ||
| Q1 24 | $171.8M | $609.5M |
| Q4 25 | $24.4M | $-847.1M | ||
| Q3 25 | $17.4M | $-263.0M | ||
| Q2 25 | $31.0M | $-546.5M | ||
| Q1 25 | $25.3M | $-175.4M | ||
| Q4 24 | $38.0M | $-224.4M | ||
| Q3 24 | $40.4M | $9.3M | ||
| Q2 24 | $37.9M | $-88.9M | ||
| Q1 24 | $43.2M | $54.1M |
| Q4 25 | 46.8% | 35.5% | ||
| Q3 25 | 51.4% | 18.1% | ||
| Q2 25 | 49.6% | 8.4% | ||
| Q1 25 | 50.0% | 21.4% | ||
| Q4 24 | 46.5% | 17.6% | ||
| Q3 24 | 53.3% | 27.1% | ||
| Q2 24 | 52.2% | 23.8% | ||
| Q1 24 | 52.4% | 62.4% |
| Q4 25 | 19.4% | -193.0% | ||
| Q3 25 | 13.2% | -37.4% | ||
| Q2 25 | 24.2% | -170.3% | ||
| Q1 25 | 21.9% | -3.3% | ||
| Q4 24 | 24.2% | 65.0% | ||
| Q3 24 | 29.8% | 17.8% | ||
| Q2 24 | 30.3% | 12.3% | ||
| Q1 24 | 27.9% | 30.4% |
| Q4 25 | 13.3% | -259.7% | ||
| Q3 25 | 9.0% | -109.4% | ||
| Q2 25 | 17.8% | -239.6% | ||
| Q1 25 | 14.8% | -45.6% | ||
| Q4 24 | 20.4% | -64.0% | ||
| Q3 24 | 21.1% | 2.1% | ||
| Q2 24 | 20.8% | -30.5% | ||
| Q1 24 | 25.1% | 8.9% |
| Q4 25 | $0.51 | $-3.03 | ||
| Q3 25 | $0.37 | $-0.96 | ||
| Q2 25 | $0.64 | $-1.99 | ||
| Q1 25 | $0.51 | $-0.65 | ||
| Q4 24 | $0.74 | $-1.10 | ||
| Q3 24 | $0.78 | $0.03 | ||
| Q2 24 | $0.73 | $-0.42 | ||
| Q1 24 | $0.81 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $226.5M |
| Total DebtLower is stronger | $608.7M | $8.2B |
| Stockholders' EquityBook value | $788.8M | $182.6M |
| Total Assets | $1.6B | $10.6B |
| Debt / EquityLower = less leverage | 0.77× | 44.78× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $226.5M | ||
| Q3 25 | $276.2M | $145.2M | ||
| Q2 25 | $231.8M | $551.1M | ||
| Q1 25 | $236.9M | $447.9M | ||
| Q4 24 | $221.6M | $492.9M | ||
| Q3 24 | $250.5M | $90.8M | ||
| Q2 24 | $217.8M | $133.0M | ||
| Q1 24 | $289.6M | $143.5M |
| Q4 25 | $608.7M | $8.2B | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | $8.9B | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $182.6M | ||
| Q3 25 | $776.7M | $1.1B | ||
| Q2 25 | $757.5M | $1.3B | ||
| Q1 25 | $751.3M | $1.8B | ||
| Q4 24 | $732.3M | $1.9B | ||
| Q3 24 | $727.7M | $1.6B | ||
| Q2 24 | $713.3M | $1.6B | ||
| Q1 24 | $672.4M | $1.7B |
| Q4 25 | $1.6B | $10.6B | ||
| Q3 25 | $1.7B | $12.0B | ||
| Q2 25 | $1.6B | $12.0B | ||
| Q1 25 | $1.6B | $13.1B | ||
| Q4 24 | $1.6B | $12.9B | ||
| Q3 24 | $1.5B | $12.0B | ||
| Q2 24 | $1.5B | $11.4B | ||
| Q1 24 | $1.6B | $10.9B |
| Q4 25 | 0.77× | 44.78× | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | 4.74× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $-76.2M |
| Free Cash FlowOCF − Capex | $24.6M | $-134.8M |
| FCF MarginFCF / Revenue | 13.4% | -41.3% |
| Capex IntensityCapex / Revenue | 4.5% | 18.0% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $-1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $-76.2M | ||
| Q3 25 | $52.6M | $-171.0M | ||
| Q2 25 | $35.6M | $-329.0M | ||
| Q1 25 | $35.1M | $-7.2M | ||
| Q4 24 | $29.0M | $445.3M | ||
| Q3 24 | $60.0M | $-20.0M | ||
| Q2 24 | $69.1M | $113.9M | ||
| Q1 24 | $55.3M | $63.0M |
| Q4 25 | $24.6M | $-134.8M | ||
| Q3 25 | $47.2M | $-231.6M | ||
| Q2 25 | $25.0M | $-726.7M | ||
| Q1 25 | $24.4M | $-262.3M | ||
| Q4 24 | $16.6M | $-210.3M | ||
| Q3 24 | $46.2M | $-367.0M | ||
| Q2 24 | $63.1M | $-493.2M | ||
| Q1 24 | $46.5M | $-457.9M |
| Q4 25 | 13.4% | -41.3% | ||
| Q3 25 | 24.6% | -96.4% | ||
| Q2 25 | 14.3% | -318.6% | ||
| Q1 25 | 14.3% | -68.2% | ||
| Q4 24 | 8.9% | -60.0% | ||
| Q3 24 | 24.1% | -82.3% | ||
| Q2 24 | 34.6% | -169.3% | ||
| Q1 24 | 27.1% | -75.1% |
| Q4 25 | 4.5% | 18.0% | ||
| Q3 25 | 2.8% | 25.2% | ||
| Q2 25 | 6.1% | 174.4% | ||
| Q1 25 | 6.3% | 66.3% | ||
| Q4 24 | 6.7% | 187.0% | ||
| Q3 24 | 7.2% | 77.8% | ||
| Q2 24 | 3.3% | 208.4% | ||
| Q1 24 | 5.1% | 85.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | 1.48× | -2.15× | ||
| Q2 24 | 1.82× | — | ||
| Q1 24 | 1.28× | 1.16× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
NFE
Segment breakdown not available.
